UroGen Pharma (URGN) Invested Capital: 2016-2025
Historic Invested Capital for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$115.4 million.
- UroGen Pharma's Invested Capital fell 552.31% to -$115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.4 million, marking a year-over-year decrease of 552.31%. This contributed to the annual value of -$8.8 million for FY2024, which is 86.50% up from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Invested Capital is -$115.4 million, which was down 23.59% from -$93.4 million recorded in Q2 2025.
- UroGen Pharma's 5-year Invested Capital high stood at $76.5 million for Q1 2021, and its period low was -$138.4 million during Q2 2023.
- Moreover, its 3-year median value for Invested Capital was -$46.5 million (2025), whereas its average is -$55.5 million.
- In the last 5 years, UroGen Pharma's Invested Capital plummeted by 1,162.18% in 2022 and then spiked by 160.76% in 2024.
- Quarterly analysis of 5 years shows UroGen Pharma's Invested Capital stood at $8.4 million in 2021, then slumped by 1,162.18% to -$89.4 million in 2022, then increased by 27.02% to -$65.2 million in 2023, then skyrocketed by 86.50% to -$8.8 million in 2024, then tumbled by 552.31% to -$115.4 million in 2025.
- Its last three reported values are -$115.4 million in Q3 2025, -$93.4 million for Q2 2025, and -$46.5 million during Q1 2025.